Published in J Exp Med on September 21, 1998
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med (2000) 3.32
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98
Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest (2003) 2.37
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med (2000) 1.90
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol (2001) 1.89
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest (2002) 1.79
Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol (2003) 1.62
GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1. J Invest Dermatol (2011) 1.56
CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med (2014) 1.50
A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol (2013) 1.50
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol (2000) 1.47
Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med (2002) 1.44
Evidence for a susceptibility gene, SLEV1, on chromosome 17p13 in families with vitiligo-related systemic lupus erythematosus. Am J Hum Genet (2001) 1.26
Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice. J Immunol (2010) 1.24
The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest (2002) 1.15
Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother (2002) 1.14
HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol (2008) 1.11
Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09
In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med (1999) 1.08
The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med (2010) 1.07
GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. J Immunol (2010) 1.05
Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J Invest Dermatol (2014) 1.03
Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One (2012) 1.01
New methods for assessing T-cell responses. Clin Diagn Lab Immunol (2000) 1.00
Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol (2013) 0.97
Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells. Proc Natl Acad Sci U S A (2013) 0.95
Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid (2010) 0.95
Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductase. Antioxid Redox Signal (2011) 0.94
Recent progress in the genetics of generalized vitiligo. J Genet Genomics (2011) 0.91
T-cell clonotypes in cancer. J Transl Med (2004) 0.91
Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol (2016) 0.86
Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes. Am J Ther (2005) 0.86
Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation. J Allergy Clin Immunol (2014) 0.85
Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology (2012) 0.84
The delicate balance of melanoma immunotherapy. Clin Transl Immunology (2013) 0.83
Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease. Clin Exp Immunol (2007) 0.82
GILT: Shaping the MHC Class II-Restricted Peptidome and CD4(+) T Cell-Mediated Immunity. Front Immunol (2013) 0.82
Detection of GAD65 autoreactive T-cells by HLA class I tetramers in type 1 diabetic patients. J Biomed Biotechnol (2009) 0.80
MHC class I multimers. Arthritis Res (2001) 0.80
Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev (2016) 0.80
Risk of generalized vitiligo is associated with the common 55R-94A-247H variant haplotype of GZMB (encoding granzyme B). J Invest Dermatol (2013) 0.79
Interleukin-4 induced down-regulation of skin homing receptor expression by human viral-specific CD8 T cells may contribute to atopic risk of cutaneous infection. Clin Exp Immunol (2005) 0.79
Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo. Clin Exp Immunol (2013) 0.79
Autoimmune complications after hematopoietic stem cell transplantation in children with nonmalignant disorders. ScientificWorldJournal (2014) 0.78
Thyroid abnormalities in paediatric patients with vitiligo: retrospective study. Postepy Dermatol Alergol (2016) 0.77
Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy. J Autoimmune Dis (2005) 0.76
Dermal mesenchymal stem cells (DMSCs) inhibit skin-homing CD8+ T cell activity, a determining factor of vitiligo patients' autologous melanocytes transplantation efficiency. PLoS One (2013) 0.76
Blood supply--susceptible formation of melanin pigment in hair bulb melanocytes of mice. Plast Reconstr Surg Glob Open (2015) 0.76
Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets. BMC Genomics (2017) 0.75
Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay. PLoS One (2016) 0.75
Treatment of vitiligo vulgaris with the combination therapy of topical steroid and vitamin D3 compound. Dermatol Reports (2012) 0.75
Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization. Med Res Rev (2016) 0.75
PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy (2016) 0.75
Plasma Levels of Interleukin-17, Interleukin-23, and Transforming Growth Factor-β in Sudanese Patients with Vitiligo: A Case-Control Study. Indian J Dermatol (2015) 0.75
Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo. Exp Dermatol (2014) 0.75
Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients. Sci Rep (2016) 0.75
Whole Transcriptome Analysis (RNA Sequencing) of Peripheral Blood Mononuclear Cells of Vitiligo Patients. Dermatopathology (Basel) (2014) 0.75
Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1. Clin Exp Immunol (2002) 0.75
Chemical-Induced Vitiligo. Dermatol Clin (2017) 0.75
Evaluation of Histologically and Histochemically Proven Cases of Vitiligo and its Correlation with CD4+ and CD8+ Lymphocyte Counts using Flow Cytometry. J Clin Diagn Res (2017) 0.75
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity (1998) 17.27
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (1994) 3.96
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol (1998) 2.68
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65
Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature (1997) 2.56
Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol (1992) 2.32
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med (1996) 2.30
Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol (1998) 2.21
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol (1994) 2.19
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
The role of tyrosinase in autoimmune vitiligo. Lancet (1994) 1.66
Antibodies to normal human melanocytes in vitiligo. J Exp Med (1983) 1.50
Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. J Immunol Methods (1997) 1.39
Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol (1996) 1.35
CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol (1995) 1.30
An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol (1993) 1.21
Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol (1997) 1.17
The binding of T cell-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated. J Biol Chem (1997) 1.15
Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol (1991) 1.13
Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol (1996) 1.05
Melanoma-associated hypopigmentation: where are the antibodies? Am J Clin Oncol (1996) 0.91
T cells in regenerating feathers of Smyth line chickens with vitiligo. Clin Immunol Immunopathol (1995) 0.89
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Eradication of schistosomiasis. Am J Public Health (1982) 10.26
Intrinsically disordered protein. J Mol Graph Model (2001) 8.54
The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators. Cell (1993) 5.91
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med (1994) 4.20
Assembly of MHC class I molecules analyzed in vitro. Cell (1990) 3.77
p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science (1995) 3.74
Intrinsic protein disorder in complete genomes. Genome Inform Ser Workshop Genome Inform (2000) 3.47
Shift in the prevalent human rotavirus detected by ribonucleic acid segment differences. Infect Immun (1980) 3.34
Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science (2000) 3.20
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med (1998) 3.04
Binding of TAFs to core elements directs promoter selectivity by RNA polymerase II. Cell (1995) 3.01
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest (1999) 3.00
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98
Presence of two distinct types of rotavirus in infants and young children hospitalized with acute gastroenteritis in Mexico City, 1977. J Infect Dis (1979) 2.84
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol (1998) 2.68
CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol (1991) 2.67
Drosophila TAFII150: similarity to yeast gene TSM-1 and specific binding to core promoter DNA. Science (1994) 2.48
Protein disorder and the evolution of molecular recognition: theory, predictions and observations. Pac Symp Biocomput (1998) 2.37
Clinical management of field worker organophosphate poisoning. West J Med (1985) 2.27
A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature (1988) 2.26
Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol (1998) 2.24
Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol (1998) 2.21
CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. Nature (1995) 2.15
Norepinephrine, vasopressin, glucagon, and A23187 induce efflux of calcium from an exchangeable pool in isolated rat hepatocytes. Proc Natl Acad Sci U S A (1978) 2.13
Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci U S A (2001) 1.99
Peptide-induced conformational change of the class I heavy chain. Nature (1991) 1.94
Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol (1999) 1.86
Intracranial bone marrow transplantation after traumatic brain injury improving functional outcome in adult rats. J Neurosurg (2001) 1.86
Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature (1987) 1.85
Coactivator and promoter-selective properties of RNA polymerase I TAFs. Science (1995) 1.82
Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature (1992) 1.79
Denitrifying Pseudomonas aeruginosa: some parameters of growth and active transport. Appl Environ Microbiol (1978) 1.79
Identification of the universally conserved core of ribonuclease P RNA. RNA (1997) 1.79
Drosophila TFIIA-L is processed into two subunits that are associated with the TBP/TAF complex. Genes Dev (1993) 1.78
Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J Immunol (2001) 1.77
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol (2000) 1.76
Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer (1996) 1.75
T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74
Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol (2000) 1.68
Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nat Med (2001) 1.66
Trypsin activation pathway of rotavirus infectivity. J Virol (1996) 1.63
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Molecular cloning and analysis of two subunits of the human TFIID complex: hTAFII130 and hTAFII100. Proc Natl Acad Sci U S A (1996) 1.59
Sequential changes of gastric hyperplastic polyps following endoscopic ligation. Zhonghua Yi Xue Za Zhi (Taipei) (2001) 1.57
The in vivo cytotoxic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules. J Exp Med (1992) 1.56
Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods (2000) 1.53
CD4+ cytolytic T cell clone confers protection against murine malaria. J Exp Med (1990) 1.51
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A (1998) 1.50
DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J Virol (1998) 1.49
Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res (2000) 1.47
Production of IL 2 and IFN-gamma by T cells from malaria patients in response to Plasmodium falciparum or erythrocyte antigens in vitro. J Immunol (1985) 1.46
OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat Immunol (2000) 1.43
Evidence for mitochondrial localization of the hormone-responsive pool of Ca2+ in isolated hepatocytes. J Biol Chem (1979) 1.42
Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. J Exp Med (1999) 1.42
Drosophila TFIIA directs cooperative DNA binding with TBP and mediates transcriptional activation. Genes Dev (1994) 1.40
Analysis of the tertiary structure of the ribonuclease P ribozyme-substrate complex by site-specific photoaffinity crosslinking. RNA (1997) 1.40
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A (2000) 1.36
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (2010) 1.36
TAP deficiency syndrome. Clin Exp Immunol (2000) 1.35
Mature dendritic cells prime functionally superior melan-A-specific CD8+ lymphocytes as compared with nonprofessional APC. J Immunol (2001) 1.34
Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A (2000) 1.33
Simulation of wheat growth and development based on organ-level photosynthesis and assimilate allocation. J Exp Bot (2010) 1.33
Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol (2000) 1.32
Regulation of the immune response in Plasmodium falciparum malaria. III. Proliferative response to antigen in vitro and subset composition of T cells from patients with acute infection or from immune donors. Clin Exp Immunol (1984) 1.32
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer (2000) 1.32
Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J Immunol (2000) 1.31
"Free" and membrane-bound ribosomes, and nature of products formed by isolated tobacco chloroplasts incubated for protein synthesis. Biochim Biophys Acta (1970) 1.31
Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res (2001) 1.31
Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci U S A (2001) 1.31
Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol (2000) 1.31
Molecular cloning and characterization of dTAFII30 alpha and dTAFII30 beta: two small subunits of Drosophila TFIID. Genes Dev (1993) 1.30
Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer (1992) 1.30
A homozygous diploid subset of commercial wine yeast strains. Antonie Van Leeuwenhoek (2005) 1.28
Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J Immunol (1999) 1.28
Alternative routes of enzymic cyanide metabolism in Pseudomonas fluorescens NCIMB 11764. Microbiology (1994) 1.28
Two modes of transvection: enhancer action in trans and bypass of a chromatin insulator in cis. Proc Natl Acad Sci U S A (1998) 1.27
CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol (1999) 1.26
Entry of rotaviruses is a multistep process. Virology (1999) 1.25
Comparison of human rotaviruses isolated in Mexico City and in Santiago, Chile, by electrophoretic migration of their double-stranded ribonucleic acid genome segments. Infect Immun (1980) 1.24
Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol (2001) 1.24
Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum. J Exp Med (1995) 1.23
An updated unified pharmacophore model of the benzodiazepine binding site on gamma-aminobutyric acid(a) receptors: correlation with comparative models. Curr Med Chem (2007) 1.22
Relative localization of viroplasmic and endoplasmic reticulum-resident rotavirus proteins in infected cells. Arch Virol (2000) 1.22
Alkaline phosphatase isoenzymes in diagnosis. Quad Sclavo Diagn (1972) 1.22